Literature DB >> 23706412

Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia.

Meredith A Reid1, Nina V Kraguljac, Kathy B Avsar, David M White, Jan A den Hollander, Adrienne C Lahti.   

Abstract

BACKGROUND: Converging evidence in schizophrenia points to disruption of the dopamine and glutamate neurotransmitter systems in the pathophysiology of the disorder. Dopamine is produced in the substantia nigra, but few neuroimaging studies have specifically targeted this structure. In fact, no studies of the substantia nigra in schizophrenia have used proton magnetic resonance spectroscopy (MRS). We sought to demonstrate the feasibility of acquiring single-voxel MRS measurements at 3T from the substantia nigra and to determine which metabolites could be reliably quantified in schizophrenia patients and healthy controls.
METHODS: We used a turbo spin echo sequence with magnetization transfer contrast to visualize the substantia nigra and single-voxel proton MRS to quantify levels of N-acetylaspartate, glutamate and glutamine (Glx), and choline in the left substantia nigra of 35 people with schizophrenia and 22 healthy controls.
RESULTS: We obtained spectra from the substantia nigra and quantified neurometabolites in both groups. We found no differences in levels of N-acetylaspartate/creatine, Glx/creatine, or choline/creatine between the groups. We found a significant correlation between Glx/creatine and overall cognitive performance, measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), in controls but not patients, a difference that was statistically significant.
CONCLUSIONS: Our study demonstrates the feasibility of obtaining single-voxel MRS data from the substantia nigra in schizophrenia. Such measurements may prove useful in understanding the biochemistry underlying cellular function in a region implicated in the pathophysiology of schizophrenia.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706412      PMCID: PMC3760722          DOI: 10.1016/j.schres.2013.04.036

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  70 in total

1.  High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia.

Authors:  Juan R Bustillo; Laura M Rowland; John Lauriello; Helen Petropoulos; Roger Hammond; Blaine Hart; William M Brooks
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

2.  Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei.

Authors:  Craig Denis Hardman; Jasmine Monica Henderson; David Isaac Finkelstein; Malcolm Kenneth Horne; George Paxinos; Glenda Margaret Halliday
Journal:  J Comp Neurol       Date:  2002-04-08       Impact factor: 3.215

3.  Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3 T.

Authors:  Jürgen Gallinat; Undine E Lang; Leslie K Jacobsen; Malek Bajbouj; Peter Kalus; Dorothea von Haebler; Frank Seifert; Florian Schubert
Journal:  J Clin Psychopharmacol       Date:  2007-02       Impact factor: 3.153

4.  Is there evidence for neurotoxicity in the prodromal and early stages of schizophrenia?

Authors:  Adrienne C Lahti; Meredith A Reid
Journal:  Neuropsychopharmacology       Date:  2011-08       Impact factor: 7.853

5.  Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia.

Authors:  T Fujimoto; T Nakano; T Takano; K Takeuchi; K Yamada; T Fukuzako; H Akimoto
Journal:  Biol Psychiatry       Date:  1996-07-01       Impact factor: 13.382

6.  Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.

Authors:  Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

7.  Creatine abnormalities in schizophrenia and bipolar disorder.

Authors:  Dost Ongür; Andrew P Prescot; J Eric Jensen; Bruce M Cohen; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2009-02-23       Impact factor: 3.222

Review 8.  A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging.

Authors:  Kristin K Haga; Yuet Peng Khor; Andrew Farrall; Joanna M Wardlaw
Journal:  Neurobiol Aging       Date:  2007-08-23       Impact factor: 4.673

9.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.

Authors:  Jean Théberge; Yousef Al-Semaan; Peter C Williamson; Ravi S Menon; Richard W J Neufeld; Nagalingam Rajakumar; Betsy Schaefer; Maria Densmore; Dick J Drost
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

10.  3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.

Authors:  Philip Tibbo; Chris Hanstock; Agitha Valiakalayil; Peter Allen
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

View more
  12 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons.

Authors:  A Ledonne; A Nobili; E C Latagliata; V Cavallucci; E Guatteo; S Puglisi-Allegra; M D'Amelio; N B Mercuri
Journal:  Mol Psychiatry       Date:  2014-09-30       Impact factor: 15.992

Review 3.  Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Authors:  Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis
Journal:  Schizophr Res       Date:  2014-01-11       Impact factor: 4.939

Review 4.  Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.

Authors:  Y Iwata; S Nakajima; T Suzuki; R S E Keefe; E Plitman; J K Chung; F Caravaggio; M Mimura; A Graff-Guerrero; H Uchida
Journal:  Mol Psychiatry       Date:  2015-06-16       Impact factor: 15.992

Review 5.  Neurobiological background of negative symptoms.

Authors:  Silvana Galderisi; Eleonora Merlotti; Armida Mucci
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

Review 6.  In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia.

Authors:  S Andrea Wijtenburg; Shaolin Yang; Bernard A Fischer; Laura M Rowland
Journal:  Neurosci Biobehav Rev       Date:  2015-01-19       Impact factor: 8.989

7.  Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.

Authors:  Eric Plitman; Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Sofia Chavez; Gladys Gómez-Cruz; Pablo León-Ortiz; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2015-08-28       Impact factor: 9.306

Review 8.  Proton Magnetic Resonance Spectroscopy: Relevance of Glutamate and GABA to Neuropsychology.

Authors:  Gabriele Ende
Journal:  Neuropsychol Rev       Date:  2015-08-12       Impact factor: 7.444

Review 9.  Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies.

Authors:  Tomomi Nakahara; Sakiko Tsugawa; Yoshihiro Noda; Fumihiko Ueno; Shiori Honda; Megumi Kinjo; Hikari Segawa; Nobuaki Hondo; Yukino Mori; Honoka Watanabe; Kazuho Nakahara; Kazunari Yoshida; Masataka Wada; Ryosuke Tarumi; Yusuke Iwata; Eric Plitman; Sho Moriguchi; Camilo de la Fuente-Sandoval; Hiroyuki Uchida; Masaru Mimura; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2021-09-28       Impact factor: 15.992

10.  The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study.

Authors:  Vladimir Grošić; Petra Folnegović Grošić; Petra Kalember; Maja Bajs Janović; Marko Radoš; Mate Mihanović; Neven Henigsberg
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.